Search Results - "Ciardiello, Amanda"

Low-Fidelity, In-Situ Pediatric Resuscitation Simulation Improves RN Competence and Self-Efficacy by Saqe-Rockoff, Ada, Ciardiello, Amanda V., Schubert, Finn D.

“…ED staff lack adequate exposure to critical pediatric patients to develop competence and confidence in resuscitation scenarios. Simulations of various designs…”
Get full text

MYCN drives oncogenesis by cooperating with the histone methyltransferase G9a and the WDR5 adaptor to orchestrate global gene transcription by Liu, Zhihui, Zhang, Xiyuan, Xu, Man, Hong, Jason J, Ciardiello, Amanda, Lei, Haiyan, Shern, Jack F, Thiele, Carol J

“…MYCN activates canonical MYC targets involved in ribosome biogenesis, protein synthesis, and represses neuronal differentiation genes to drive oncogenesis in…”
Get full text

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma by Coffey, David G., Maura, Francesco, Gonzalez-Kozlova, Edgar, Diaz-Mejia, J. Javier, Luo, Ping, Zhang, Yong, Xu, Yuexin, Warren, Edus H., Dawson, Travis, Lee, Brian, Xie, Hui, Smith, Eric, Ciardiello, Amanda, Cho, Hearn J., Rahman, Adeeb, Kim-Schulze, Seunghee, Diamond, Benjamin, Lesokhin, Alexander, Kazandjian, Dickran, Pugh, Trevor J., Green, Damian J., Gnjatic, Sacha, Landgren, Ola

“…The role of the immune microenvironment in maintaining disease remission in patients with multiple myeloma (MM) is not well understood. In this study, we…”
Get full text

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma by Yellapantula, Venkata, Hultcrantz, Malin, Rustad, Even H., Wasserman, Ester, Londono, Dory, Cimera, Robert, Ciardiello, Amanda, Landau, Heather, Akhlaghi, Theresia, Mailankody, Sham, Patel, Minal, Medina-Martinez, Juan Santiago, Arango Ossa, Juan Esteban, Levine, Max Fine, Bolli, Niccolo, Maura, Francesco, Dogan, Ahmet, Papaemmanuil, Elli, Zhang, Yanming, Landgren, Ola

“…Recent genomic research efforts in multiple myeloma have revealed clinically relevant molecular subgroups beyond conventional cytogenetic classifications…”
Get full text

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma by Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, Korde, Neha

“…Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective…”
Get full text

Improving Thermoregulation for Trauma Patients in the Emergency Department: An Evidence-Based Practice Project by Saqe-Rockoff, Ada, Schubert, Finn D, Ciardiello, Amanda, Douglas, Elizabeth

“…Extensive evidence exists on the association between hypothermia and increased morbidity and mortality in trauma patients. Gaps in practice related to…”
Get full text

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma by Yellapantula, Venkata, Hultcrantz, Malin, Rustad, Even H., Wasserman, Ester, Londono, Dory, Cimera, Robert, Ciardiello, Amanda, Landau, Heather, Akhlaghi, Theresia, Mailankody, Sham, Patel, Minal, Medina-Martinez, Juan Santiago, Ossa, Juan Esteban Arango, Levine, Max Fine, Bolli, Niccolo, Maura, Francesco, Dogan, Ahmet, Papaemmanuil, Elli, Zhang, Yanming, Landgren, Ola

“…A correction to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myeloma by Eveillard, Marion, Rustad, Even, Roshal, Mikhail, Zhang, Yanming, Ciardiello, Amanda, Korde, Neha, Hultcrantz, Malin, Lu, Sydney, Shah, Urvi, Hassoun, Hani, Smith, Eric, Lesokhin, Alexander, Mailankody, Sham, Landgren, Ola, Thoren, Katie

“…Summary Matrix‐assisted laser desorption ionisation time‐of‐flight mass spectrometry (MALDI‐TOF MS) may soon replace routine electrophoretic methods for…”
Get full text

Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy by Eveillard, Marion, Korde, Neha, Ciardiello, Amanda, Diamond, Benjamin, Lesokhin, Alexander, Mailankody, Sham, Smith, Eric, Hassoun, Hani, Hultcrantz, Malin, Shah, Urvi, Lu, Sydney, Salcedo, Meghan, Werner, Kelly, Rispoli, Jenna, Mastey, Donna, Landgren, Ola, Thoren, Katie

“…•The highest M−protein detection rates occur with MALDI-TOF MS plus FLC measurement.•MALDI-TOF MS can help accurately determine complete response status in…”
Get full text

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets by Shah, Urvi A, Maclachlan, Kylee H, Derkach, Andriy, Salcedo, Meghan, Barnett, Kelly, Caple, Julia, Blaslov, Jenna, Tran, Linh, Ciardiello, Amanda, Burge, Miranda, Shekarkhand, Tala, Adintori, Peter, Cross, Justin, Pianko, Matthew J, Hosszu, Kinga, McAvoy, Devin, Mailankody, Sham, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Tan, Carlyn R, Lu, Sydney X, Patel, Dhwani, Diamond, Benjamin, Shah, Gunjan, Scordo, Michael, Lahoud, Oscar, Chung, David J, Landau, Heather, Usmani, Saad Z, Giralt, Sergio, Taur, Ying, Landgren, C Ola, Block, Gladys, Block, Torin, Peled, Jonathan U, van den Brink, Marcel R M, Lesokhin, Alexander M

“…Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome is affected by diet, and in…”
Get full text

Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience by Ciardiello, Amanda, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi A, Lu, Sydney X., Patel, Dhwani, Maclachlan, Kylee, Lahoud, Oscar Boutros, Shah, Gunjan L., Scordo, Michael, Chung, David J., Landau, Heather Jolie, Giralt, Sergio, Derkach, Andriy, Usmani, Saad Zafar, Lesokhin, Alexander M., Tan, Carlyn Rose Co

“…e20005 Background: DARA has been FDA approved for newly diagnosed multiple myeloma (NDMM) in combination with lenalidomide/dexamethasone (Rd),…”
Get full text

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma by Eveillard, Marion, Rustad, Even H, Roshal, Mikhail, Zhang, Yanming, Ciardiello, Amanda Kathryn, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Smith, Eric L, Lesokhin, Alexander M., Mailankody, Sham, Landgren, Ola, Thoren, Katie

“…Introduction In multiple myeloma (MM), the absence of measurable residual disease (MRD) after completed therapy is associated with longer progression free…”
Get full text

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study by Diamond, Benjamin, Korde, Neha, Lesokhin, Alexander M., Smith, Eric L, Shah, Urvi A, Mailankody, Sham, Hultcrantz, Malin, Hassoun, Hani, Lu, Sydney X., Tan, Carlyn, Massey, Donna, Salcedo, Meghan, Diab, Victoria, Werner, Kelly, Rispoli, Jenna, Sams, Allison, Verducci, Dennis, Jones, Katie, Schlossman, Julia, Chansakul, Aisara, Harrison, Angela, Ciardiello, Amanda Kathryn, Tavitian, Elizabet, Shekarkhand, Tala, Piacentini, Casey, Rustad, Even H, Yellapantula, Venkata D, Maura, Francesco, Peterson, Tim J, Derkach, Andriy, Devlin, Sean, Landau, Heather J, Scordo, Michael, Chung, David J., Shah, Gunjan L., Lahoud, Oscar B, Thoren, Katie, Murata, Kazunori, Ramanathan, Lakshmi, Arcila, Maria E., Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Giralt, Sergio A., Landgren, Ola

“…Background. Consensus from prior studies shows that the use of maintenance therapy after completion of combination therapy leads to longer progression-free…”
Get full text

Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma by Eveillard, Marion, Rustad, Even, Roshal, Mikhail, Zhang, Yanming, Ciardiello, Amanda, Korde, Neha, Hultcrantz, Malin, Hassoun, Hani, Smith, Eric L., Lesokhin, Alexander M., Mailankody, Sham, Landgren, Carl Ola, Thoren, Katie

“…Abstract only e19525 Background: Minimal residual disease (MRD) negativity after completed therapy is associated with longer progression-free survival (PFS) in…”
Get full text

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study by Landgren, Ola, Mastey, Donna, Lesokhin, Alexander M., Smith, Eric L, Shah, Urvi A, Mailankody, Sham, Hultcrantz, Malin, Hassoun, Hani, Lu, Sydney X, Salcedo, Meghan, Diab, Victoria, Werner, Kelly, Rispoli, Jenna, Sams, Allison, Verducci, Dennis, Jones, Katie, Schlossman, Julia, Chansakul, Aisara, Harrison, Angela, Ciardiello, Amanda, Tavitian, Elizabeth, Shekarkhand, Tala, Rustad, Even, Yellapantula, Venkata, Maura, Francesco, Peterson, Tim J, Devlin, Sean M., Landau, Heather J, Scordo, Michael, Chung, David J., Shah, Gunjan, Lahoud, Oscar B, Thoren, Katie, Murata, Kazunori, Ramanathan, Lakshmi, Arcila, Maria E, Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Giralt, Sergio, Korde, Neha

“…Background. Prior studies consistently show that the use of maintenance therapy after completion of combination therapy translates into longer progression-free…”
Get full text